what's next for NextSeed

Houston-based online fundraising platform launches new turnkey retail space opportunity

The Waffle Bus' brick-and-mortar location is NextSeed Space's first tenant. Courtesy of NextSeed

Houston-based NextSeed makes it easier for retail and restaurant startups to get funding, and the company is releasing a new line of services to help these startups on the next step after funding: Finding retail space.

NextSeed Space now exists to help consumer-facing companies have access to move-in-ready spaces with short-term leases. The idea is to give the concept a low-risk place to debut their business, generate customers, and work out the kinks of their business model before locking in a permanent location.

"One of the biggest hurdles for a small business is the build-out process," Abe Chu, CMO of NextSeed says in the release. "A talented chef or designer might be very skilled at their craft, but many other factors are critical to opening a storefront including the capital raise, lease negotiation, design, permitting, construction and marketing. Finding ways to assist the entrepreneur in reducing complexity and controlling risks at this juncture is critical."

NextSeed has partnered with Greenway Plaza, where it offices, to bring turnkey retail space in The Hub, a new, recently renovated space in the office park.

The first NextSeed Space tenant is Houston's The Waffle Bus, which just raised $107,000 on the NextSeed fundraising platform. While the company has a popular brand and fleet of trucks, retail space has changed in Houston, and leasing companies are looking for safe tenants, the release says, meaning it's become more difficult for new tenants to find an ideal space.

"We see what's happening in the marketplace as our window to minimize obstacles for everyone's gain," Chu says in the release. "You've got creative small businesses that lack experience and funds, banks and investors that rely on longer leases for capital, and landlords who are not always equipped to handle the additional time and resources necessary to curate and nurture a revolving mix of pop-up tenants."

NextSeed's fundraising platform launched around four years ago and, since then, has helped almost 50 companies raise money totaling more than $10 million. NextSeed co-founder and CEO, Youngro Lee, spoke to InnovationMap last fall about how the company has grown and is always looking to expand.

"The goal was for NextSeed to keep innovating and bring in new technologies and processes," Lee says.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted